MeSH D016393 - b-cell lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Acrotech Biopharma | Ibritumomab tiuxetan | Zevalin |  | 2002-02-19 |  |  |
| Amgen | Rituximab | Riabni |  | 2020-12-17 |  |  |
| Biogen | Rituximab | Rituxan |  | 2002-02-19 |  |  |
| Bristol Myers Squibb | Lisocabtagene maraleucel | Breyanzi |  | 2022-04-04 | $400 M | Q2/23-Q1/24 |
| Ceft BioPharma | Ibritumomab tiuxetan | Zevalin |  | 2004-01-16 |  |  |
| Celgene | Lisocabtagene maraleucel | Breyanzi |  | 2021-02-05 |  |  |
| Celltrion | Rituximab | Blitzima |  | 2017-07-13 |  |  |
| Rituximab | Ritemvia |  | 2017-07-13 |  |  | |
| Rituximab | Rituzena (previously Tuxella) |  | 2017-07-13 |  |  | |
| Rituximab | Truxima |  | 2018-11-28 |  |  | |
| Genentech | Rituximab | Rituxan |  | 1997-11-26 |  |  |
| Rituximab, Hyaluronidase (human recombinant) | Rituxan Hycela |  | 2017-06-22 |  |  | |
| Johnson & Johnson | Ibrutinib | Imbruvica |  | 2014-10-21 | $3,265 M | Y2023 |
| Orphan Medical | Loncastuximab tesirine | Zynlonta |  | 2022-12-20 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
79%74/94
Phase 2
21%23/111
Phase 3
20%7/35
Approved: 6Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use